Online inquiry

IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6089MR)

This product GTTS-WQ6089MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6089MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1927MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ1639MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ13705MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ7073MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ6987MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ6757MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DS-1062
GTTS-WQ15798MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ10098MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LA480
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW